Skip to main content
OncoTargets and Therapy logoLink to OncoTargets and Therapy
. 2019 Jul 5;12:5375. doi: 10.2147/OTT.S212592

The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy [Corrigendum]

PMCID: PMC6616134  PMID: 31308703

Yang M, Qin X, Qin G, Zheng X. Onco Targets Ther. 2019;12:2171–2180.

On page 2172, Chemotherapy regimens section in Table 1, Platinum + platinum (TP) should have been Docetaxel + platinum (TP); Platinum + cyclophosphamide (TC) should have been Docetaxel + cyclophosphamide (TC).


Articles from OncoTargets and therapy are provided here courtesy of Dove Press

RESOURCES